DoubleDown Interactive to Report 2025 Fourth Quarter Results on February 11 and Host Conference Call and Webcast February 6, 2026
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential February 6, 2026
Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook February 6, 2026
Shorla Oncology® Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma February 6, 2026
MEXC 2025 Report: Zero-Fee Strategy Delivers $1.1B in User Savings, Capturing Leading Market Share February 6, 2026